Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Daylight photodynamic therapy of actinic keratosis without curettage is as effective as with curettage: a randomized clinical trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical phenotypes of hidradenitis suppurativa

    Research output: Contribution to journalLetterResearchpeer-review

  1. Localization of treatment-resistant areas in patients with psoriasis on biologics

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. 1151PGOBLET CELL CARCINOIDS: CHARACTERISTICS OF A DANISH COHORT OF 83 PATIENTS

    Research output: Contribution to journalJournal articleResearchpeer-review

  • K S Tveit
  • A Duvetorp
  • M Østergaard
  • L Skov
  • K Danielsen
  • L Iversen
  • O Seifert
View graph of relations

BACKGROUND: There are scarce data in Scandinavia about treatment satisfaction among patients with psoriasis (PsO) and/or psoriatic arthritis (PsA). The number of patients receiving systemic treatment is unknown.

OBJECTIVE: To describe patients' experience of treatments for PsO/PsA in Sweden, Denmark and Norway, addressing communication with physicians, satisfaction with treatment and concerns regarding treatment options.

METHODS: The NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP) asked 22 050 adults (randomly selected from the YouGov panels in Sweden, Denmark and Norway) whether they had PsO/PsA. A total of 1264 individuals who reported physician-diagnosed PsO/PsA were invited to participate in the full survey; 96.6% responded positively.

RESULTS: Systemic treatment use was reported by 14.6% (biologic: 8.1%) of respondents with PsO only and by 58.5% (biologic: 31.8%) of respondents with PsA. Biologic treatments were more frequently reported by respondents considering their disease severe (26.8% vs 6.7% non-severe) and those who were members of patient organizations (40.7% vs 6.9% non-members). Discussing systemic treatments with their physician was reported significantly more frequently by respondents with PsA, those perceiving their disease as severe (although 35.2% had never discussed systemic treatment with their physician) and those reporting being a member of a patient organization (P < 0.05). Many respondents reported health risk concerns and dissatisfaction with their treatment. Of special interest was that respondents aged 45-75 years reported less experience with biologics (8.1%) than those aged 18-44 years (21.5%). The older respondents also reported more uncertainty regarding long-term health risks related to systemic treatments (most [66.7-72.9%] responded 'do not know' when asked about the risk of systemic options).

CONCLUSION: It appears likely that substantial numbers of Scandinavians suffering from severe PsO/PsA are not receiving optimal treatment from a patient perspective, particularly older patients. Also, one-third of respondents with severe symptoms had never discussed systemic treatment with a physician.

Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology : JEADV
Volume33
Issue number2
Pages (from-to)340-354
Number of pages15
ISSN0926-9959
DOIs
Publication statusPublished - Feb 2019

Bibliographical note

COPECARE

    Research areas

  • Adult, Aged, Arthritis, Psoriatic/diagnosis, Biological Products/administration & dosage, Denmark, Dermatologic Agents/administration & dosage, Female, Humans, Male, Middle Aged, Norway, Patient Satisfaction/statistics & numerical data, Psoriasis/diagnosis, Risk Assessment, Surveys and Questionnaires, Sweden, Treatment Outcome

ID: 59067425